Is DECREASED APPETITE a side effect of SORAFENIB (RAF KINASE INHIBITOR) ? ( FactMed.com )

About this FactMed analysis covering adverse side effect reports of SORAFENIB (RAF KINASE INHIBITOR) patients who developed DECREASED APPETITE.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 226 individuals taking SORAFENIB (RAF KINASE INHIBITOR) reported DECREASED APPETITE to the FDA. A total of 3329 SORAFENIB (RAF KINASE INHIBITOR) drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between SORAFENIB (RAF KINASE INHIBITOR) and DECREASED APPETITE. In doing so, we compare SORAFENIB (RAF KINASE INHIBITOR) with other drugs that cause DECREASED APPETITE, to help you evaluate whether or not SORAFENIB (RAF KINASE INHIBITOR) causes DECREASED APPETITE. Likewise, this page shows the most highly-reported side effects of SORAFENIB (RAF KINASE INHIBITOR), so you can see if DECREASED APPETITE ranks among SORAFENIB (RAF KINASE INHIBITOR)'s most well-known side effects.

Summary Statistics
Reports of SORAFENIB (RAF KINASE INHIBITOR) causing DECREASED APPETITE: 226
Reports of any side effect of SORAFENIB (RAF KINASE INHIBITOR) : 3329
Percentage of SORAFENIB (RAF KINASE INHIBITOR) patients where DECREASED APPETITE is a reported side effect: 6.7888%

FDA reports of any drug causing DECREASED APPETITE : 44396
Average percentage for all medicated patients where DECREASED APPETITE is reported as a complication: 0.2782%

Physician opinion on SORAFENIB (RAF KINASE INHIBITOR) as adverse event culprit:

Overall opinion for all reports of this drug:

Most frequent diagnoses/indications for prescribing SORAFENIB (RAF KINASE INHIBITOR):

HEPATIC NEOPLASM MALIGNANT ( 770 patients )
RENAL CELL CARCINOMA ( 114 patients )
THYROID CANCER ( 65 patients )
METASTATIC RENAL CELL CARCINOMA ( 44 patients )
THYROID CANCER METASTATIC ( 35 patients )
BREAST CANCER ( 31 patients )
BREAST CANCER METASTATIC ( 27 patients )
GASTRIC CANCER ( 25 patients )
NON-SMALL CELL LUNG CANCER ( 25 patients )
COLORECTAL CANCER METASTATIC ( 22 patients )
RENAL CANCER ( 17 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 14 patients )
BILE DUCT CANCER ( 14 patients )
SALIVARY GLAND CANCER ( 7 patients )
HEPATIC CANCER METASTATIC ( 7 patients )
COLORECTAL CANCER ( 7 patients )
SMALL CELL LUNG CANCER STAGE UNSPECIFIED ( 6 patients )
RECTAL CANCER ( 5 patients )
PANCREATIC CARCINOMA ( 4 patients )
PROSTATE CANCER ( 4 patients )
INTRAOCULAR MELANOMA ( 4 patients )
HEPATIC NEOPLASM MALIGNANT RECURRENT ( 3 patients )
NEOPLASM ( 3 patients )
LIVER DISORDER ( 3 patients )
ANGIOSARCOMA ( 3 patients )
NON-SMALL CELL LUNG CANCER STAGE IV ( 3 patients )
METASTASES TO LUNG ( 3 patients )
HEPATIC NEOPLASM MALIGNANT NON-RESECTABLE ( 3 patients )
COLORECTAL CANCER STAGE IV ( 3 patients )
NEOPLASM MALIGNANT ( 3 patients )
GALLBLADDER CANCER METASTATIC ( 3 patients )
BILIARY CANCER METASTATIC ( 3 patients )
METASTASIS ( 3 patients )
COLON CANCER METASTATIC ( 2 patients )
HYPOPHARYNGEAL CANCER ( 2 patients )
DESMOID TUMOUR ( 2 patients )
NEUROENDOCRINE CARCINOMA ( 2 patients )
ACUTE MYELOID LEUKAEMIA (IN REMISSION) ( 2 patients )
LUNG NEOPLASM MALIGNANT ( 2 patients )
OESOPHAGEAL CARCINOMA ( 2 patients )
METASTATIC MALIGNANT MELANOMA ( 2 patients )
TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED ( 2 patients )
METASTATIC SQUAMOUS CELL CARCINOMA ( 2 patients )
ANGINA PECTORIS ( 2 patients )
RENAL CELL CARCINOMA STAGE IV ( 2 patients )
OSTEOSARCOMA METASTATIC ( 2 patients )
BONE SARCOMA ( 2 patients )
METASTATIC OCULAR MELANOMA ( 2 patients )
METASTATIC SALIVARY GLAND CANCER ( 2 patients )
TONSIL CANCER ( 2 patients )
MYELODYSPLASTIC SYNDROME ( 1 patients )
PROSTATE CANCER METASTATIC ( 1 patients )
GALLBLADDER CANCER ( 1 patients )
NEUROENDOCRINE TUMOUR ( 1 patients )
MALIGNANT NEOPLASM OF RENAL PELVIS ( 1 patients )
GLIOMA ( 1 patients )
BLADDER CANCER ( 1 patients )
OVARIAN CANCER METASTATIC ( 1 patients )
CAROTID ARTERY DISEASE ( 1 patients )
HEPATOBLASTOMA ( 1 patients )
NASOPHARYNGEAL CANCER ( 1 patients )
ACUTE MYELOID LEUKAEMIA ( 1 patients )
LUNG ADENOCARCINOMA ( 1 patients )
RENAL CANCER METASTATIC ( 1 patients )
DIFFUSE LARGE B-CELL LYMPHOMA ( 1 patients )
NEUROENDOCRINE CARCINOMA OF THE SKIN ( 1 patients )
MALIGNANT HISTIOCYTOSIS ( 1 patients )
ANTICOAGULANT THERAPY ( 1 patients )
MALIGNANT SOFT TISSUE NEOPLASM ( 1 patients )
SARCOMA ( 1 patients )
GERM CELL CANCER ( 1 patients )
OESOPHAGEAL ADENOCARCINOMA ( 1 patients )
SQUAMOUS CELL CARCINOMA ( 1 patients )
HEAD AND NECK CANCER ( 1 patients )
OVARIAN EPITHELIAL CANCER ( 1 patients )
( 0 patients )

Drugs with high FDA adverse event association with DECREASED APPETITE:

BYETTA (7201 patients)
ASPIRIN (3713 patients)
METFORMIN HCL (2457 patients)
HEPARIN SODIUM INJECTION (2391 patients)
LASIX (1899 patients)
NEXAVAR (1871 patients)
FOSAMAX (1848 patients)
ZOMETA (1793 patients)
LIPITOR (1652 patients)
LANTUS (1577 patients)
LISINOPRIL (1519 patients)
OMEPRAZOLE (1478 patients)
PREDNISONE (1441 patients)
NEXIUM (1414 patients)
SYNTHROID (1325 patients)
FORTEO (1323 patients)
SEROQUEL (1308 patients)
HUMIRA (1305 patients)
DIGOXIN (1269 patients)
FUROSEMIDE (1240 patients)
COUMADIN (1213 patients)
OXYCONTIN (1205 patients)
SIMVASTATIN (1203 patients)
GLUCOPHAGE (1198 patients)
XANAX (1186 patients)
RIBAVIRIN (1153 patients)
CHANTIX (1142 patients)
ACTOS (1132 patients)
LYRICA (1113 patients)
AREDIA (1082 patients)
FOLIC ACID (1058 patients)
ACETAMINOPHEN (1055 patients)
ATENOLOL (1042 patients)
PRILOSEC (1029 patients)
SANDOSTATIN LAR (1025 patients)
CYMBALTA (1022 patients)
NEURONTIN (1021 patients)
AMARYL (1011 patients)
ZOLOFT (1005 patients)
VICTOZA (989 patients)
NORVASC (981 patients)
POTASSIUM CHLORIDE (952 patients)
FLUOROURACIL (943 patients)
DEXAMETHASONE (939 patients)
PREDNISOLONE (937 patients)
PROTONIX (932 patients)
PLAVIX (931 patients)
HYDROCHLOROTHIAZIDE (927 patients)
AMBIEN (914 patients)
METHOTREXATE (897 patients)
GLIPIZIDE (891 patients)
DIOVAN (884 patients)
XELODA (883 patients)
DECADRON (878 patients)
REVLIMID (874 patients)
VITAMIN D (864 patients)
ALLOPURINOL (864 patients)
PAXIL (864 patients)
AVANDIA (824 patients)
METFORMIN (821 patients)
ATIVAN (817 patients)
LEVAQUIN (814 patients)
LEVOTHYROXINE SODIUM (795 patients)
GLYBURIDE (789 patients)
WARFARIN SODIUM (785 patients)
VIOXX (784 patients)
ALBUTEROL (761 patients)
ZOFRAN (754 patients)
REBETOL (742 patients)
LEXAPRO (738 patients)
ZOCOR (736 patients)
ENBREL (735 patients)
AVASTIN (734 patients)
LORAZEPAM (732 patients)
PREVACID (725 patients)
PERCOCET (719 patients)
OXYCODONE HCL (713 patients)
AMLODIPINE (692 patients)
TOPROL-XL (687 patients)
PEG-INTRON (686 patients)
REMICADE (682 patients)
PEGASYS (679 patients)
CALCIUM (665 patients)
CISPLATIN (663 patients)
CRESTOR (660 patients)
EXJADE (654 patients)
GABAPENTIN (653 patients)
METOPROLOL TARTRATE (646 patients)
CLONAZEPAM (645 patients)
HUMALOG (628 patients)
STRATTERA (625 patients)
VICODIN (625 patients)
ADVAIR DISKUS 100/50 (611 patients)
SUTENT (610 patients)
IBUPROFEN (610 patients)
GLEEVEC (610 patients)
ACCUTANE (606 patients)
TYSABRI (588 patients)
MORPHINE (582 patients)
LANSOPRAZOLE (580 patients)
CELEBREX (577 patients)
INSULIN (564 patients)
MULTI-VITAMINS (555 patients)
CARBOPLATIN (551 patients)
COREG (550 patients)
COMPAZINE (532 patients)
ALPRAZOLAM (530 patients)
PREDNISONE TAB (523 patients)
DIAZEPAM (522 patients)
SPIRIVA (518 patients)
DURAGESIC-100 (505 patients)
EFFEXOR (505 patients)
VELCADE (501 patients)
PROZAC (499 patients)
TELAVIC (TELAPREVIR) (497 patients)
ZANTAC (494 patients)
SPIRONOLACTONE (485 patients)
AMOXICILLIN (471 patients)
TAXOTERE (471 patients)
ALDACTONE (469 patients)
AVONEX (469 patients)
CAPECITABINE (468 patients)
CELEXA (467 patients)
FAMOTIDINE (463 patients)
MULTI-VITAMIN (461 patients)
TRAMADOL HCL (460 patients)
KLONOPIN (459 patients)
OXALIPLATIN (454 patients)
NITROGLYCERIN (452 patients)
ENALAPRIL MALEATE (451 patients)
ALLEGRA (441 patients)
LORTAB (439 patients)
MAGNESIUM OXIDE (424 patients)
METOPROLOL (422 patients)
SINGULAIR (418 patients)
RANITIDINE (416 patients)
VITAMIN B-12 (415 patients)
AFINITOR (410 patients)
PRISTIQ (409 patients)
NOVOLOG (408 patients)
VALIUM (405 patients)
FENTANYL (405 patients)
VALTREX (402 patients)
REGLAN (395 patients)
CALCIUM CARBONATE (395 patients)
ZYRTEC (392 patients)
WELLBUTRIN (390 patients)
TOPAMAX (389 patients)
DILAUDID (389 patients)
RISPERDAL (385 patients)
COLACE (379 patients)
PANTOPRAZOLE (375 patients)
TRAZODONE HCL (374 patients)
FISH OIL (370 patients)
MORPHINE SULFATE (366 patients)
PREMARIN (365 patients)
TYLENOL (CAPLET) (360 patients)
HYDROCODONE (359 patients)
PROMETHAZINE (358 patients)
ZITHROMAX (356 patients)
AMITRIPTYLINE HCL (356 patients)
POTASSIUM (356 patients)
ARIMIDEX (355 patients)
ASCORBIC ACID (353 patients)
GLIMEPIRIDE (351 patients)
CIPROFLOXACIN (350 patients)
ARANESP (350 patients)
TYKERB (350 patients)
TAXOL (347 patients)
LOPRESSOR (346 patients)
CARVEDILOL (344 patients)
SUBOXONE (343 patients)
MIRTAZAPINE (341 patients)
COZAAR (341 patients)
CONCERTA (340 patients)
LEUCOVORIN CALCIUM (339 patients)
FEMARA (338 patients)
MS CONTIN (338 patients)
ALTACE (336 patients)
CYCLOPHOSPHAMIDE (335 patients)
ERLOTINIB HYDROCHLORIDE (333 patients)
MUCOSTA (331 patients)
ACYCLOVIR (331 patients)
ZYPREXA (330 patients)
ZETIA (330 patients)
BACTRIM (329 patients)
URSO 250 (328 patients)
IRON (327 patients)
PRADAXA (326 patients)
DAYTRANA (324 patients)
CITALOPRAM HYDROBROMIDE (323 patients)
LOVENOX (321 patients)
RADIATION THERAPY (319 patients)
FLOMAX (318 patients)
ARICEPT (318 patients)
ALENDRONATE SODIUM (317 patients)
PEPCID (316 patients)
REBIF (316 patients)
THALIDOMIDE (313 patients)
TASIGNA (313 patients)
DIFLUCAN (313 patients)
METOCLOPRAMIDE (312 patients)
MEGACE (310 patients)
FLUCONAZOLE (309 patients)
ONDANSETRON (309 patients)
EXELON (309 patients)
VITAMIN E (307 patients)
FERROUS SULFATE TAB (307 patients)
REMERON (306 patients)
CLONIDINE (305 patients)

Most common side effects for patients taking SORAFENIB (RAF KINASE INHIBITOR):

DIARRHOEA (613 patients)
HEPATIC FAILURE (378 patients)
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME (342 patients)
HEPATIC ENCEPHALOPATHY (320 patients)
FATIGUE (300 patients)
RASH (276 patients)
ASCITES (253 patients)
ABDOMINAL PAIN (237 patients)
DECREASED APPETITE (226 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (198 patients)
PYREXIA (191 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (179 patients)
NAUSEA (165 patients)
HYPERTENSION (160 patients)
ASTHENIA (154 patients)
DEHYDRATION (140 patients)
HEPATIC FUNCTION ABNORMAL (133 patients)
DYSPNOEA (131 patients)
CONFUSIONAL STATE (131 patients)
HYPOKALAEMIA (125 patients)
ALOPECIA (124 patients)
VOMITING (118 patients)
CONSTIPATION (115 patients)
INTERSTITIAL LUNG DISEASE (114 patients)
LEFT VENTRICULAR DYSFUNCTION (113 patients)
DEATH (113 patients)
ENDOCARDITIS (112 patients)
ARTHRALGIA (111 patients)
STOMATITIS (111 patients)
ABDOMINAL PAIN UPPER (110 patients)
JAUNDICE (108 patients)
HEPATIC NEOPLASM MALIGNANT (106 patients)
GASTROINTESTINAL HAEMORRHAGE (106 patients)
RETINAL VASCULAR THROMBOSIS (103 patients)
LOWER GASTROINTESTINAL HAEMORRHAGE (103 patients)
LIVER CARCINOMA RUPTURED (101 patients)
OEDEMA PERIPHERAL (97 patients)
PLEURAL EFFUSION (97 patients)
STAPHYLOCOCCAL INFECTION (96 patients)
PNEUMONIA BACTERIAL (96 patients)
ENTEROBACTER INFECTION (96 patients)
MYOPATHY (95 patients)
DRY MOUTH (94 patients)
PAIN IN EXTREMITY (93 patients)
ANXIETY (90 patients)
MALAISE (89 patients)
PULMONARY EMBOLISM (85 patients)
ANAEMIA (84 patients)
PLATELET COUNT DECREASED (81 patients)
BACK PAIN (79 patients)
SEPSIS (78 patients)
PRURITUS (78 patients)
DUODENAL ULCER (77 patients)
MIGRAINE (76 patients)
MITRAL VALVE INCOMPETENCE (76 patients)
HYPOGLYCAEMIA (76 patients)
C-REACTIVE PROTEIN INCREASED (74 patients)
BLOOD PRESSURE INCREASED (73 patients)
VARICES OESOPHAGEAL (73 patients)
HEADACHE (72 patients)
RETINAL VEIN OCCLUSION (72 patients)
ABASIA (69 patients)
RENAL FAILURE ACUTE (69 patients)
WEIGHT DECREASED (67 patients)
DEEP VEIN THROMBOSIS (67 patients)
DIZZINESS (65 patients)
ERYTHEMA (65 patients)
GENERAL PHYSICAL HEALTH DETERIORATION (64 patients)
CONVULSION (63 patients)
ALANINE AMINOTRANSFERASE INCREASED (62 patients)
DYSPHONIA (62 patients)
CEREBRAL HAEMORRHAGE (60 patients)
APHAGIA (58 patients)
COLITIS (58 patients)
PNEUMONIA (57 patients)
GASTRIC ULCER (56 patients)
HYPONATRAEMIA (55 patients)
HAEMOGLOBIN DECREASED (53 patients)
RESPIRATORY FAILURE (52 patients)
LUNG DISORDER (52 patients)
CEREBRAL ISCHAEMIA (49 patients)
PARAESTHESIA (49 patients)
BLOOD BILIRUBIN INCREASED (48 patients)
GAIT DISTURBANCE (48 patients)
THYROID CANCER METASTATIC (44 patients)
DEPRESSED LEVEL OF CONSCIOUSNESS (43 patients)
PERICARDIAL EFFUSION (41 patients)
THROMBOCYTOPENIA (41 patients)
BLISTER (41 patients)
FEBRILE NEUTROPENIA (40 patients)
BLOOD LACTATE DEHYDROGENASE INCREASED (40 patients)
HALLUCINATION (40 patients)
CHILLS (40 patients)
AMMONIA INCREASED (39 patients)
SKIN ULCER (39 patients)
BLOOD ALKALINE PHOSPHATASE INCREASED (38 patients)
PAIN (38 patients)
HYPOALBUMINAEMIA (38 patients)
HYPOCALCAEMIA (37 patients)
FALL (37 patients)
POLLAKIURIA (37 patients)
BLOOD PRESSURE DECREASED (37 patients)
SKIN EXFOLIATION (37 patients)
INSOMNIA (36 patients)
CARDIAC ARREST (36 patients)
HYPOAESTHESIA (35 patients)
INFECTIOUS PERITONITIS (35 patients)
MYOCARDIAL INFARCTION (35 patients)
RETINAL VASCULAR DISORDER (34 patients)
RENAL FAILURE (34 patients)
LIPASE INCREASED (34 patients)
HYPERKALAEMIA (33 patients)
HYPERGLYCAEMIA (33 patients)
HAEMOPTYSIS (31 patients)
ATRIAL FIBRILLATION (30 patients)
GENERALISED OEDEMA (30 patients)
FAECAL INCONTINENCE (30 patients)
WHITE BLOOD CELL COUNT DECREASED (30 patients)
CELLULITIS (29 patients)
CHEST PAIN (29 patients)
SOMNOLENCE (29 patients)
HYPERBILIRUBINAEMIA (28 patients)
HYPOTENSION (28 patients)
MUSCLE SPASMS (28 patients)
ABDOMINAL DISTENSION (27 patients)
WHITE BLOOD CELL COUNT INCREASED (27 patients)
VISION BLURRED (27 patients)
HEPATIC PAIN (26 patients)
BLOOD ALBUMIN DECREASED (26 patients)
DYSURIA (25 patients)
RASH GENERALISED (25 patients)
BLOOD SODIUM DECREASED (25 patients)
BLOOD URIC ACID INCREASED (25 patients)
COMA (25 patients)
COUGH (25 patients)
PANCYTOPENIA (25 patients)
ACUTE ABDOMEN (24 patients)
EOSINOPHIL COUNT INCREASED (24 patients)
CEREBROVASCULAR ACCIDENT (24 patients)
METASTASES TO CENTRAL NERVOUS SYSTEM (23 patients)
CEREBRAL INFARCTION (23 patients)
HYPOMAGNESAEMIA (23 patients)
RETINAL VEIN THROMBOSIS (23 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (23 patients)
TUMOUR LYSIS SYNDROME (22 patients)
HYPOPHOSPHATAEMIA (22 patients)
INFECTION (22 patients)
ORAL PAIN (22 patients)
BLOOD CREATININE INCREASED (22 patients)
NEUTROPENIA (22 patients)
RENAL IMPAIRMENT (22 patients)
LETHARGY (22 patients)
SKIN TOXICITY (21 patients)
TONGUE BLISTERING (21 patients)
LIVER ABSCESS (21 patients)
HAEMATEMESIS (21 patients)
OESOPHAGEAL VARICES HAEMORRHAGE (20 patients)
MENTAL IMPAIRMENT (20 patients)
NERVOUSNESS (20 patients)
NEPHROTIC SYNDROME (20 patients)
HYPOPHAGIA (20 patients)
ADRENAL INSUFFICIENCY (19 patients)
DRY SKIN (19 patients)
BLOOD AMYLASE INCREASED (19 patients)
OEDEMA (19 patients)
INFECTIOUS PLEURAL EFFUSION (19 patients)
DYSPEPSIA (19 patients)
COMA HEPATIC (19 patients)
HEART RATE INCREASED (18 patients)
HYPERTENSIVE CRISIS (18 patients)
MYALGIA (18 patients)
ECZEMA (18 patients)
URINARY TRACT INFECTION (18 patients)
NEUROMYOPATHY (18 patients)
MEDICAL DEVICE COMPLICATION (18 patients)
DIVERTICULITIS (18 patients)
OSTEOMYELITIS (18 patients)
CEREBRAL ATROPHY (18 patients)
CEREBRAL VENTRICLE DILATATION (18 patients)
DIABETIC FOOT INFECTION (18 patients)
NECK PAIN (18 patients)
OLIGURIA (17 patients)
GASTROINTESTINAL DISORDER (17 patients)
HAEMATOCHEZIA (17 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (17 patients)
HYPOTHYROIDISM (17 patients)
TRANSAMINASES INCREASED (17 patients)
OROPHARYNGEAL PAIN (17 patients)
CHRONIC MYELOID LEUKAEMIA (17 patients)
NEOPLASM PROGRESSION (17 patients)
METASTASES TO ADRENALS (16 patients)
LYMPHOCYTE COUNT DECREASED (16 patients)
INTERNATIONAL NORMALISED RATIO INCREASED (16 patients)
MULTI-ORGAN FAILURE (16 patients)
FEAR (16 patients)
PANCREATIC CARCINOMA (16 patients)
HYPERSOMNIA (16 patients)
EPILEPSY (16 patients)
SUBARACHNOID HAEMORRHAGE (16 patients)
METASTASES TO LUNG (16 patients)
TACHYCARDIA (16 patients)
MUSCULAR WEAKNESS (16 patients)
KLEBSIELLA SEPSIS (16 patients)
MYOCARDIAL ISCHAEMIA (16 patients)
DYSGEUSIA (16 patients)
LUNG INFECTION (16 patients)
FAECES DISCOLOURED (16 patients)
PAIN OF SKIN (16 patients)
SPINAL FRACTURE (16 patients)
PANIC REACTION (16 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.

Recent FactMed Activity for SORAFENIB (RAF KINASE INHIBITOR)

Issue	Description / Topic	Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about DECREASED APPETITE and SORAFENIB (RAF KINASE INHIBITOR), post it here. You may receive a response from a fellow patient - or a leading expert in the field.

Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking SORAFENIB (RAF KINASE INHIBITOR), post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.

Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in SORAFENIB (RAF KINASE INHIBITOR). This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.

We are currently accepting registration for SORAFENIB (RAF KINASE INHIBITOR) experts. If you are a healthcare provider experienced in prescribing SORAFENIB (RAF KINASE INHIBITOR), please register here.